Atrium Therapeutics, Inc. (RNA)
| Market Cap | 202.78M |
| Revenue (ttm) | 18.62M +70.9% |
| Net Income | -49.50M |
| EPS | -3.19 |
| Shares Out | 15.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,771 |
| Open | 12.88 |
| Previous Close | 12.96 |
| Day's Range | 12.84 - 13.19 |
| 52-Week Range | 11.95 - 16.77 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 65.75 (+403.06%) |
| Earnings Date | Jun 9, 2026 |
About RNA
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is h... [Read more]
Financial Performance
In 2025, Atrium Therapeutics's revenue was $18.62 million, an increase of 70.85% compared to the previous year's $10.90 million. Losses were -$49.50 million, 97.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for RNA stock is "Buy." The 12-month stock price target is $65.75, which is an increase of 403.06% from the latest price.
News
Atrium Therapeutics earns $15M development milestone payment from Bristol Myers
Atrium Therapeutics (RNA) has earned a $15M development milestone payment from Bristol Myers (BMY). The milestone was achieved upon the successful delivery of a development candidate for the first lic...
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced...
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment Ind...
Atrium Therapeutics initiated with an Overweight at Wells Fargo
Wells Fargo analyst Yanan Zhu initiated coverage of Atrium Therapeutics (RNA) with an Overweight rating and $25 price target The firm sees a “significant” opportunity for the company’s’ antibody oligo...
Atrium Therapeutics launches as newly independent, publicly traded company
Atrium Therapeutics (RNA) launched as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-th...
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinic...
Novartis completes acquisition of Avidity Biosciences
Novartis (NVS) announced that it has successfully completed its acquisition of Avidity Biosciences (RNA). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of...
Why Is Avidity Biosciences Stock (RNA) Down Today?
Avidity Biosciences stock appeared to take a beating on Friday following a deal with Novartis.
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligon...
One new option listing and one option delisting on February 26th
New option listings for February 26th include Avidity Biosciences, Inc. (RNAM). Option delistings effective February 26th include Avidity Biosciences (RNA).
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligon...
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing Treatment demonstrated improvements in multiple measures i...
Avidity Biosciences announces expected record date for spin-off
Avidity Biosciences (RNA) announced that its board of directors has designated the close of business, Eastern Time, on February 12 as the record date for the pro rata distribution of
Avidity Biosciences Announces Expected Record Date for Spin-Off
SAN DIEGO, Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonu...
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypoch...
Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools and automated labs to unlock efficiency gains across their pipeline.
Avidity Biosciences downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Avidity Biosciences (RNA) to In Line from Outperform with a price target of $72, up from $65. Novartis (NVS) has agreed to acquire Avidity for $72 per
Avidity reports FTC granted request for early termination of HSR waiting period
In a regulatory filing, Avidity Biosciences (RNA) noted that as previously disclosed, the company entered into an Agreement and Plan of Merger, dated as of October 25, 2025, with Novartis
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company...
Avidity Biosciences downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Ritu Baral downgraded Avidity Biosciences (RNA) to Hold from Buy with a price target of $74, down from $78, after the company entered into a merger agreement
Avidity Biosciences downgraded to Neutral from Buy at Citi
Citi analyst Geoff Meacham downgraded Avidity Biosciences (RNA) to Neutral from Buy with an unchanged price target of $72 after the company entered into a merger agreement with Novartis (NVS)
Avidity Biosciences downgraded to Neutral from Buy at Chardan
Chardan analyst Keay Nakae downgraded Avidity Biosciences (RNA) to Neutral from Buy with a $72 price target after Novartis (NVS) announced an agreement to acquire Avidity for $72 per share
Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avidi...